The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2026-07-11), Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio is 7.18.
Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) 3-Year Sortino Ratio Explanation
The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Laboratorios Farmaceuticos Rovi 3-Year Sortino Ratio Related Terms
LABFF vs ZTS, UTHR, VTRS: 3-Year Sortino Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi 3-Year Sortino Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio falls into.
Laboratorios Farmaceuticos Rovi 3-Year Sortino Ratio Calculation
The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Laboratorios Farmaceuticos Rovi (LABFF) has a 3-Year Sortino Ratio of 7.18 as of Jul. 11, 2026. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio too high?
Laboratorios Farmaceuticos Rovi's current 3-Year Sortino Ratio is 7.18. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's 3-Year Sortino Ratio of 7.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Sortino Ratio for a Drug Manufacturers company?
A good 3-Year Sortino Ratio depends on the Drug Manufacturers industry context. However, 3-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Sortino Ratio mean?
A high 3-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current 3-Year Sortino Ratio is 7.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current 3-Year Sortino Ratio of 7.18. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current 3-Year Sortino Ratio is 7.18. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Sortino Ratio calculated?
3-Year Sortino Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current 3-Year Sortino Ratio is 7.18 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
3-Year Sortino Ratio: 7.18
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
3-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 